Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Global Registry to Gather Data on Natural History of Patients With Hereditary Angioedema Type I and II (HGR)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03828279
Recruitment Status : Recruiting
First Posted : February 4, 2019
Last Update Posted : February 5, 2019
Sponsor:
Information provided by (Responsible Party):
HAE Global Registry Foundation

Brief Summary:
The objective of this international hereditary angioedema (HAE) register is to collect homogeneous clinical and laboratory data on patients with HAE type I and II gathering better information on the natural course of the disease and detecting therapeutic options to manage it.

Condition or disease Intervention/treatment
Hereditary Angioedema Type I and II Diagnostic Test: functional and antigenic C1 inhibitor

Detailed Description:

It is an international multicenter disease registry, the principal investigator at each center is responsible for competent ethic committee/institutional review board approval and for identifying co-investigators, who collect patients' informed consent and insert patients' data. Participating patients own their data. Upon acceptance of the informed consent, the treating physician transfers data of the case report form (CRF) to a specifically designed electronic support (eCRF) and the patients enter data on attacks. Physicians at center fill-in the eCRF with data for demography, diagnosis, prophylaxis and associated diseases. Plasma levels of C1 inhibitor antigen and function and of C4 antigen document laboratory diagnostic criteria. Each patient has a national identifier code. Patients fill-in attack reports that encompass duration, severity and treatment of each angioedema episode. C1 inhibitor coding gene (SERPING1) genotype is entered according to the last Hugo nomenclature. Yearly update of information is recommended, patients with follow up above two years are moved in a separate area and excluded from analysis. Each patient prospectively fills data on attacks. On a specific informed consent, the patient can agree on storing biological material (plasma and nucleic acids) for research purposes.

The data processor is an innovative start-up (Cloud-R s.r.l. Milan, Italy) that manages all data according to a specific contract and in compliance with current regulation on sensitive data security and processing. The Registry, delivered in the mode of Registry-as-a-Service (RaaS), is designed following General Data Protection Regulation (GDPR) guidelines, and issues regular software and infrastructure enhancements as a part of the normal operational mode. The system generates statistics of aggregated anonymized data following the participating centers' hierarchy levels and Global Registry governance rules. Patients supply data on attacks either on paper support or using a Web form or a mobile application. These data will flow into a staging area for physician validation before being considered valid for statistics. For each entry the system updates in real-time all the statistics and dashboards. The platform has configurable functionalities to support data quality management. It provides data format validation, integration to external qualified libraries, alerts, dashboards, automatic index calculations, advanced filters and queries, data change log. This open architecture, allows integration of the system, via standard API's, to external or sub-registries, registries, biobanks and clinical bioinformatics tools, i.e. for specific trial studies leveraging a specific cluster of patients already present in the Global Registry.

An independent non-profit foundation (HGRF) made of representatives of patients' associations is in charge for funding and delegates all the management to the HAE Global Registry Board (HGRB). The HGRB is in charge for operational, assisted by the HAE Global Registry Scientific Committee (HGRSC) for topics of competence. No registry member, center, group or board can access the entire set of data. All registry members, as single or group, can propose studies based on aggregated data by addressing the request to the HGRSC. Analysis and studies of data at local centers can occur at any time. Members of HGRB and HGRSC are elected to be representative of different cultural and geographic backgrounds. Their offices have a two-year term with no more than one consecutive renewal. Angioedema centers can join the Registry upon request to the HGRB . The registry quality control system periodically checks Registry entries and compliance of eCRF with the source data. For each information, the system will grant traceability of time and author.

Layout table for study information
Study Type : Observational [Patient Registry]
Estimated Enrollment : 220 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 1 Year
Official Title: The Global Registry on Hereditary Angioedema Type I and II
Actual Study Start Date : October 1, 2017
Estimated Primary Completion Date : December 31, 2019
Estimated Study Completion Date : December 31, 2023

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
hereditary angioedema type I
Patients were diagnosed as C1 inhibitor HAE type I when functional and antigenic C1 inhibitor were ≤ 50% of normal
Diagnostic Test: functional and antigenic C1 inhibitor
Diagnosis of HAE is based on personal and/or family history of angioedema and on C1 inhibitor functional or antigenic plasma levels ≤50% of normal.
Other Name: genetic analysis

hereditary angioedema type II
Patients were diagnosed as type II when functional C1 inhibitor was ≤50% and antigenic was >50% of normal
Diagnostic Test: functional and antigenic C1 inhibitor
Diagnosis of HAE is based on personal and/or family history of angioedema and on C1 inhibitor functional or antigenic plasma levels ≤50% of normal.
Other Name: genetic analysis




Primary Outcome Measures :
  1. Number of angioedema events [ Time Frame: Through study completion, an average of 5 years ]
    Number of angioedema events

  2. Time of angioedema events [ Time Frame: Through study completion, an average of 5 years ]
    Time in hours of presence of angioedema symptoms

  3. Severity of angioedema events [ Time Frame: through study completion, an average of 5 years ]
    Number of severe, moderate, mild angioedema symptoms based on a three point scale patient reported outcome


Secondary Outcome Measures :
  1. Comorbidities [ Time Frame: Through study completion , an average of 5 years ]
    Number and type of comorbidities recorded according to the International Classification of Diseases 9 codes

  2. Treatment-Emergent comorbidities [ Time Frame: Through study completion , an average of 5 years ]
    Incidence of comorbidities emerging in patients exposed to specific treatments

  3. Treatment efficacy [ Time Frame: Through study completion , an average of 5 years ]
    Hours of presence of angioedema symptoms during specific long term prophylaxis


Biospecimen Retention:   Samples With DNA
Sodium Citrate samples are collected form patients for testing plasma levels of C1 inhibitor antigen and function and C4 antigen. Cells are collected for DNA extraction and detection of mutations in SERPING1


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
patients diagnosed with HAE type I and II and followed by a referral center for angioedema
Criteria

Inclusion Criteria:

  • patients diagnosed with HAE type I and II with signed informed consent
  • laboratory diagnostic criteria documenting plasma levels of C1 inhibitor antigen and function and of C4 antigen

Exclusion Criteria:

  • patients without HAE type I and II
  • patients without documented laboratory diagnostic criteria
  • patients not capable to give informed consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03828279


Contacts
Layout table for location contacts
Contact: marco cicardi, MD +39 0239042516 marco.cicardi@unimi.it

Locations
Layout table for location information
Italy
ASST FBF Sacco Recruiting
Milan, Italy, 20157
Contact: marco cicardi, M.D.    +3950319829    marco.cicardi@unimi.it   
Sponsors and Collaborators
HAE Global Registry Foundation
Investigators
Layout table for investigator information
Principal Investigator: marco cicardi, MD HAE Global Registry Foundation
Additional Information:

Layout table for additonal information
Responsible Party: HAE Global Registry Foundation
ClinicalTrials.gov Identifier: NCT03828279    
Other Study ID Numbers: HAERegistry
First Posted: February 4, 2019    Key Record Dates
Last Update Posted: February 5, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: All registry members, as single or group, can propose studies based on aggregated anonymized data by addressing the request to the HAE Global Registry Scientific Committee (HGRSC)
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
Time Frame: entire study period
Access Criteria: to be a member of the HAERegistry and have the approval of the HGRSC to analyze data

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by HAE Global Registry Foundation:
angioedema
disease registry
C1 inhibitor
anti bradykinin treatments
Additional relevant MeSH terms:
Layout table for MeSH terms
Angioedema
Angioedemas, Hereditary
Hereditary Angioedema Types I and II
Vascular Diseases
Cardiovascular Diseases
Urticaria
Skin Diseases, Vascular
Skin Diseases
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Hereditary Complement Deficiency Diseases
Primary Immunodeficiency Diseases
Genetic Diseases, Inborn
Immunologic Deficiency Syndromes